October 6, 2009

HELIX BIOPHARMA PROVIDES UPDATES ON TOPICAL INTERFERON ALPHA-2B AND L-DOS47 FOLLOWING PRE-IND MEETINGS WITH THE U.S. FDA (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug (“pre-IND”) meetings with the U.S. Food and Drug Administration (“FDA”).